Download PDF
Geburtshilfe Frauenheilkd 2002; 62(11): 1060-1068
DOI: 10.1055/s-2002-35974
Übersicht

Georg Thieme Verlag Stuttgart · New York

Ein multifaktorielles Modell zur Ätiologie des Ovarialkarzinoms

A Multifactorial Model for Ovarian Cancer EtiologyR. von Georgi1 , K. Münstedt2
  • 1 Abteilung für Medizinische Soziologie der Justus-Liebig-Universität Gießen
  • 2 Frauenklinik des Universitätsklinikums Gießen
Further Information

Publication History

Eingang Manuskript: 12. April 2002 Eingang revidiertes Manuskript: 9. September 2002

Akzeptiert: 20. September 2002

Publication Date:
05 December 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für das Ovarialkarzinom (OK), die fünfthäufigste Krebserkrankung der Frau, ist eine Reihe verschiedener Risikofaktoren identifiziert worden. Diese führten zu drei unterschiedlichen Entstehungsmodellen, der Hyperovulations-, der Gonadotropin- und der Entzündungshypothese. Alle Modelle werden dabei unabhängig voneinander diskutiert. Erklärungsansätze aus dem Bereich der Psychoneuroimmunologie und -endokrinologie blieben bisher unberücksichtigt. In dem vorliegenden Artikel werden die unterschiedlichen Vorstellungen in ein dreidimensionales Prozessmodell (3DPOK-Modell) integriert, welches spezifische und generelle Risikofaktoren sowie unterschiedliche Ebenen kausaler Bedingungsfaktoren und den Verlauf der Erkrankung berücksichtigt. Das 3DPOK-Modell verbindet somit unterschiedliche Forschungsrichtungen zur Ätiologie des OK, setzt Variablen der Prävention, Behandlung und Nachsorge in eine mögliche Beziehung und erlaubt die zielgerichtete Generierung von Hypothesen für die weitere Forschung.

Abstract

The three major hypotheses that have been formulated to explain the etiology of ovarian cancer are the incessant ovulation hypothesis, the gonadotropin hypothesis, and the inflammation hypothesis. All models were formulated without reference to the others or to psychoneuroimmunologic approaches and psychoneuroendocrinology. We integrated the three hypotheses regarding the pathogenesis of ovarian cancer into a three-dimensional process model (3DPOK model). This model takes into account specific and general risk factors, and the concepts mentioned above. The model combines the different approaches to the etiology of ovarian cancer and illustrates possible relationships between the variables of prevention, treatment and follow-up. It may facilitate the generation of hypotheses for further research.

Schlüsselwörter

Ovarialkarzinom - Ätiologie - Entstehungsmodell - Prognose - 3DPOK-Modell

Key words

Ovarian carcinoma - etiology - hypothesis - prognosis - 3DPOK model

Literatur

  • 1 Ader R, Cohen N, Felton D. Psychoneuroimmunology: interactions between the nervous system and the immune system.  Lancet. 1995;  345 99-103
    CrossrefPubMedGoogle Scholar
  • 2 Akhmedkhanov A A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig K L, Shore R E. Aspirin and risk of epithelial cancer. 32nd Annual Meeting of the Society of Gynecologic Oncologist (SGO). Nashville, Tennessee March 3 - 7, 2001. 
    Google Scholar
  • 3 Alagoz T, Buller R E, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA125 level?.  Gynecol Oncol. 1994;  53 93-97
    CrossrefPubMedGoogle Scholar
  • 4 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland .Krebs in Deutschland. 3. erweiterte, aktualisierte Ausgabe. Saarbrücken; Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland 2002
    Google Scholar
  • 5 Auersperg N, Wong A ST, Choi K-C, Kang S K, Leung P CK. Ovarian surface epithelium: biology, endocrinology and pathology.  Endocr Rev. 2001;  22 255-289
    CrossrefPubMedGoogle Scholar
  • 6 Balkwill F R. Re: Possible role of ovarian epithelial inflammation in ovarian cancer.  J Natl Cancer I. 2000;  92 162-163
    PubMedGoogle Scholar
  • 7 Berchuk A, Carney M. Human ovarian cancer of the surface epithelium.  Biochem Pharmacol. 1997;  54 541-544
    CrossrefPubMedGoogle Scholar
  • 8 Bergquist A, Bruse C, Carlberg M, Carlström K. Interleukin 1β, interleukin-6, and tumor necrosis factor-a in endometriotic tissue and in endometrium.  Fertil Steril. 2001;  75 489-495
    CrossrefPubMedGoogle Scholar
  • 9 Biondi M. Effects of stress on immune function: an overview. Ader E, Felten DL, Cohen N Psychoneuroimmunology. Vol. 2. 3rd ed. San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo; Academic Press 2001: 189-226
    Google Scholar
  • 10 Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans: the last two decades of research.  Psychother Psychosom. 1999;  68 114-150
    PubMedGoogle Scholar
  • 11 Brinton L A, Hoover R N. Epidemiology of gynecologic cancers. Hoskins WJ, Perez CA, Young RC Principles and Practice of Gynecologic Oncology. Philadelphia; Lippincott-Raven 1997: 3-29
    Google Scholar
  • 12 Buller R E, Skilling J S, Sood A A, Plaxe S, Baergen R N, Lager D J. Field cancerization: why late “recurrent” ovarian cancer is not recurrent.  Am J Obstet Gynecol. 1998;  178 641-649
    PubMedGoogle Scholar
  • 13 Butow P N, Hiller J E, Price M A, Thackway S V, Kricker A, Tennat C C. Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer.  J Psychosom Res. 2000;  49 169-181
    CrossrefPubMedGoogle Scholar
  • 14 Casagrande J T, Louie E W, Pike M C, Ross R K, Henderson B E. “Incessant ovulation” and ovarian cancer.  Lancet. 1979;  2 170-173
    PubMedGoogle Scholar
  • 15 Cella D F, Orav E J, Kornblith A B. et al . Socioeconomic status and cancer survival.  J Clin Oncol. 1991;  9 1500-1509
    PubMedGoogle Scholar
  • 16 Chakravarti S, Collins W P, Forecast J D, Newton J R, Oram D H, Studd J W. Hormonal profiles after the menopause.  Brit Med J. 1976;  2 784-787
    PubMedGoogle Scholar
  • 17 Chan Y M, Ngan H YS, Yip P SF, Li B YG, Lau O WK, Tang G WK. Psychosocial adjustment in gynecologic cancer survivors: a longitudinal study on risk factors for maladjustment.  Gynecol Oncol. 2001;  80 387-394
    CrossrefPubMedGoogle Scholar
  • 18 Chiaffarino F, Parazzini F, Negri E. et al . Time since last birth and the risk of ovarian cancer.  Gynecol Oncol. 2001;  81 233-236
    CrossrefPubMedGoogle Scholar
  • 19 Cohen S, Williamson G M. Stress and infectious disease in humans.  Psychol Bull. 1991;  109 5-24
    CrossrefPubMedGoogle Scholar
  • 20 Conte D, Romanelli F, Fillo S. et al . Aspirin inhibits androgen response to chorionic gonadotropin in humans.  Am J Physiol-Endoc M. 1999;  277 E1032-E1037
    PubMedGoogle Scholar
  • 21 Cramer D W, Harlow B L, Titus-Ernstoff L, Bohlke K, Welch W R, Greenberg E R. Over-the-counter analgesics and risk of ovarian cancer.  Lancet. 1998;  351 104-107
    CrossrefPubMedGoogle Scholar
  • 22 Cramer D W, Welch W R, Hutchison G B, Willett W, Scully R E. Dietary animal fat in relation to ovarian cancer risk.  Obstet Gynecol. 1984;  63 833-838
    PubMedGoogle Scholar
  • 23 Cramer D W, Welch W R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis.  J Natl Cancer I. 1983;  71 717-721
    PubMedGoogle Scholar
  • 24 Dantzer R, Kelley K W. Stress and immunity: an integrated view of relationships between the brain and the immune system.  Life Sci. 1989;  44 1995-2008
    CrossrefPubMedGoogle Scholar
  • 25 de la Fuente J R, Rosenbaum A H. Psychoneuroendocrinology.  Mayo Clin Proc. 1979;  54 109-118
    PubMedGoogle Scholar
  • 26 Del Priore G, Robischon K, Phipps W R. et al . Risk of ovarian cancer after treatment for infertility.  N Engl J Med. 1995;  332 1300-1302
    CrossrefPubMedGoogle Scholar
  • 27 Eccles D M, Cranston G, Steel C M, Nakamura Y, Leonard R CF. Allele losses on chromosome 17 in human epithelial ovarian carcinoma.  Oncogene. 1990;  5 1599-1601
    PubMedGoogle Scholar
  • 28 Ellsworth L R, Allen H H, Nisker J A. Ovarian function after radical hysterectomy for stage Ib carcinoma of the cervix.  Am J Obstet Gynecol. 1983;  145 185
    PubMedGoogle Scholar
  • 29 Erzen M, Rakar S, Klancar B, Syrjänen S. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.  Gynecol Oncol. 2001;  83 100-108
    CrossrefPubMedGoogle Scholar
  • 30 Eysenck H J. The biological basis of personality. Springfield, Illinois; Charles C. Thomas 1967
    Google Scholar
  • 31 Eysenck H J. Sexualität und Persönlichkeit. Wien; Europaverlag 1977
    Google Scholar
  • 32 Eysenck H J. The respective importance of personality, cigarette smoking and interaction effects for the genesis of cancer and coronary heart disease.  Pers Indiv Differ. 1988;  9 453-464
    CrossrefPubMedGoogle Scholar
  • 33 Eysenck H J. Personality and cancer. Cooper CL Handbook of Stress, Medicine, and Health. Volume 10. Boca Raton; CRC Press 1996: 193-215
    Google Scholar
  • 34 Eysenck H J, Eysenck M W. Personality and individual differences. A natural science approach. New York, London; Plenum Press 1985
    Google Scholar
  • 35 Eysenck H J, Eysenck S BG. Psychoticism as a dimension of personality. London, Sydney, Auckland, Toronto; Hodder Stroughton 1976
    Google Scholar
  • 36 Faller H. Krankheitsbewältigung und Überlebenszeit bei Krebskranken.  Psychotherapeut. 2001;  46 20-35
    CrossrefPubMedGoogle Scholar
  • 37 Fathalla M F. Incessant ovulation - A factor in ovarian neoplasia?.  Lancet. 1971;  2 163
    PubMedGoogle Scholar
  • 38 Frank T S. Testing for hereditary risk of breast and ovarian cancer.  Community Genet. 2000;  3 193-197
    CrossrefPubMedGoogle Scholar
  • 39 Frentzel-Beyme R, Grossarth-Maticek R. The interaction between risk factors and self-regulation in the development of chronic diseases.  Int J Hyg Environ Health. 2001;  204 81-88
    CrossrefPubMedGoogle Scholar
  • 40 Friedlander M L. Prognostic factors in ovarian cancer.  Semin Oncol. 1998;  25 305-314
    PubMedGoogle Scholar
  • 41 Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Clinical significance of expression of estrogen receptor α and β mRNAs in ovarian cancers.  Oncology. 2000;  58 334-341
    CrossrefPubMedGoogle Scholar
  • 42 Gertig D M, Hunter D J, Cramer D W. et al . Prospective study of talc use and ovarian cancer.  J Natl Cancer I. 2000;  92 249-252
    PubMedGoogle Scholar
  • 43 Goldberg J M, Piver M S, Jishi M F, Blumenson L. Age at onset of ovarian cancer in woman with a strong family history of ovarian cancer.  Gynecol Oncol. 1997;  66 3-9
    CrossrefPubMedGoogle Scholar
  • 44 Green A, Purdie D, Bain C, Siskind V, Webb P M. Cigarette smoking and risk of epithelial ovarian cancer (Australia).  Cancer Cause Control. 2001;  12 713-719
    PubMedGoogle Scholar
  • 45 Greenlee R T, Hill-Harmon M B, Murray T, Thun M. Cancer statistics, 2001.  CA-Cancer J Clin. 2001;  51 15-36
    CrossrefPubMedGoogle Scholar
  • 46 Greggi S, Parazzini F, Paratore P P. et al . Risk factors for ovarian cancer in central Italy.  Gynecol Oncol. 2000;  79 50-54
    CrossrefPubMedGoogle Scholar
  • 47 Grossarth-Maticek R, Eysenck H J, Heeb J, Costa S D, Diel I J. Interactions of psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment.  J Clin Psychol. 2000;  56 33-50
    CrossrefPubMedGoogle Scholar
  • 48 Gwin M L, Lee N, Rhodes P H, Layde P M, Rubin G. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer.  J Clin Epidemiol. 1989;  43 559-568
    PubMedGoogle Scholar
  • 49 Haberland J, Bertz J, Görsch B, Schön D. Krebsinzidenzschätzung für Deutschland mittels log-linearer Modelle.  Gesundheitswesen. 2001;  63 556-560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Harlap S, Olson S, Akhmedkhanov A. et al . Epithelial ovarian carcinoma and European birthplace of grandparents.  Gynecol Oncol. 2001;  81 25-32
    CrossrefPubMedGoogle Scholar
  • 51 Harlow B L, Hartge P A. A review of perineal talc exposure and risk of ovarian cancer.  Regul Toxicol Pharm. 1995;  21 254-260
    PubMedGoogle Scholar
  • 52 Harris R, Whittemore A S, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white woman. Collaborative ovarian cancer group.  Am J Epidemiol. 1992;  136 1204-1211
    PubMedGoogle Scholar
  • 53 Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriois in epithelial ovarian cancer.  Int J Gynecol Obstet. 1997;  59 245-250
    CrossrefPubMedGoogle Scholar
  • 54 Katsnis W A, Shields L BE, Spinnato J A, Gercel-Taylor C, Taylor D D. Immune recognition of endometrial tumor antigens induced by multiparity.  Gynecol Oncol. 1998;  70 33-39
    CrossrefPubMedGoogle Scholar
  • 55 Kavan M G, Engdahl B E, Kay S. Colon cancer: personality factors predictive of onset and stage of presentation.  J Psychosom Res. 1995;  39 1031-1039
    CrossrefPubMedGoogle Scholar
  • 56 Konishi I, Kuroda H, Mandai M. Review: Gonadotropins and development of ovarian cancer.  Oncology. 1999;  57 45-48
    PubMedGoogle Scholar
  • 57 Kreitler S, Levavi H, Bornstein G. Personality factors and cervical premalignancy.  Pers indiv Differ. 1996;  21 883-890
    CrossrefPubMedGoogle Scholar
  • 58 Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma.  Gynecol Oncol. 1998;  69 192-196
    CrossrefPubMedGoogle Scholar
  • 59 Langdon S P, Smyth J F. Growth factors and ovarian cancer.  Endocr Relat Cancer. 1998;  5 283-291
    CrossrefPubMedGoogle Scholar
  • 60 Lingeman C H. Environmental factors in the etiology of carcinoma of the human ovary: a review.  J Ind Med. 1983;  4 365-379
    PubMedGoogle Scholar
  • 61 Löffler G, Petrides P E. Biochemie und Pathobiochemie. 6. korrig. Aufl. Berlin, Heidelberg, New York, Barcelona, Budapest, Hongkong, London, Mailand, Paris, Singapur, Tokio; Springer 1998
    Google Scholar
  • 62 Lu J J, Zheng Y, Kang X. et al . Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.  Gynecol Oncol. 2000;  79 158-168
    CrossrefPubMedGoogle Scholar
  • 63 Lynch H T, Schuelke G S, Wells I C, Cheng S C, Kimberling W J, Biscone K A. Hereditary ovarian carcinoma: biomarker studies.  Cancer. 1985;  55 410-415
    PubMedGoogle Scholar
  • 64 Maes M, Van Bockstaele D R, Van Gastel A V. et al . The effects of psychological stress on leukocyte subsets distribution in humans: evidence of immune activation.  Neuropsychobiology. 1999;  29 1-9
    PubMedGoogle Scholar
  • 65 Makar A P. Hormone therapy in epithelial ovarian cancer.  Endocr Relat Cancer. 2000;  7 85-93
    CrossrefPubMedGoogle Scholar
  • 66 Mandai M, Konishi I, Kuroda H. et al . Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas.  Eur J Cancer. 1997;  33 1501-1507
    CrossrefPubMedGoogle Scholar
  • 67 Marchbanks P A, Wilson H, Bastos E, Cramer D W, Schildkraut J M, Peterson H B. Cigarette smoking and epithelial ovarian cancer by histologic type.  Obstet Gynecol. 1998;  81 283-287
    PubMedGoogle Scholar
  • 68 Marchetti B, Guarcello G, Triolo G, Morale M C, Farinella Z, Scapagnini U. Luteinizing hormone-releasing hormone (LHRH) as natural messenger in neuro-immune-endocrine communicatio. Hadden JW, Masek K, Nistico G Interactions Among Central Nervous System, Neuroendocrine and Immune System. Rome, Milan; Pythagora Press 1989: 127-145
    Google Scholar
  • 69 Marchetti B, Morale M C, Gallo F. et al .The hypothalamo-pituitary-gonadal axis and the immune system. Ader E, Felten DL, Cohen N Psychoneuroimmunology. Vol. 1. 3rd ed. San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo; Academic Press 2001: 362-389
    Google Scholar
  • 70 McNeilly A S. Suckling and the control of gonadotropin secretion. Knobil E, Neill JD The Physiology of Reproduction. Vol. 2. 2nd ed. New York; Raven Press 1994: 1179-1212
    Google Scholar
  • 71 Miyazaki M, Nagy A, Schally A V. et al . Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.  J Natl Cancer I. 1997;  89 1803-1809
    PubMedGoogle Scholar
  • 72 Modan B, Ron E, Lerner-Geva L. et al . Cancer incidence in a cohort of infertile women.  Am J Epidemiol. 1998;  147 1038-1042
    CrossrefPubMedGoogle Scholar
  • 73 Mosgaard B J, Lidegaard O, Krüger Kjaer S. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study.  Fertil Steril. 1997;  67 1005-1012
    CrossrefPubMedGoogle Scholar
  • 74 Mosgaard B J, Lidegaard O, Krüger Kjaer S, Schou G, Andersen A N. Ovarian stimulation and borderline ovarian tumors: a case-control study.  Fertil Steril. 1998;  10 1049-1055
    PubMedGoogle Scholar
  • 75 Münstedt K, Steen J, Knauf A G, Buch T, von Georgi R, Franke F E. Steroid hormone receptors and long term survival in invasive ovarian cancer.  Cancer. 2000;  89 1783-1791
    CrossrefPubMedGoogle Scholar
  • 76 Münstedt K, Lange S, Hadji P, von Georgi R. Möglichkeiten der Prävention von Tumorerkrankungen.  Frauenarzt. 2001;  42 1083-1097
    PubMedGoogle Scholar
  • 77 Murdoch W J. Proteolytic and cellular death mechanisms in ovulatory ovarian rupture.  Biol Signal Recept. 2000;  9 102-114
    PubMedGoogle Scholar
  • 78 Narod A S, Risch H, Moslehi R. et al . Oral contraceptives and the risk of hereditary ovarian cancer.  N Engl J Med. 1998;  339 424-428
    CrossrefPubMedGoogle Scholar
  • 79 Nash M A, Ferrandina G, Gordinier M, Loercher A, Freedman R S. The role of cytokines in both the normal and malignant ovary.  Endocr Relat Cancer. 1999;  6 98-107
    PubMedGoogle Scholar
  • 80 Ness R B, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer.  J Natl Cancer I. 1999;  91 1459-1467
    PubMedGoogle Scholar
  • 81 O'Leary A. Stress, emotion, and the human immune function.  Psychol Bull. 1990;  108 363-382
    CrossrefPubMedGoogle Scholar
  • 82 Ördög T, Chen M-D, O'Byrne K T. et al . On the mechanism of lactational anovulation in the rhesus monkey.  Am J Physiol-Endoc M. 1998;  37 665-676
    PubMedGoogle Scholar
  • 83 Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings.  J Steroid Biochem. 2000;  74 357-364
    PubMedGoogle Scholar
  • 84 Peterson C M, Jolles C J, Carrell D T. et al . GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience.  Gynecol Oncol. 1994;  52 26-30
    CrossrefPubMedGoogle Scholar
  • 85 Pike M C, Spicer D V. Hormonal contraception and chemoprevention of female cancers.  Endocr Relat Cancer. 2000;  7 73-83
    CrossrefPubMedGoogle Scholar
  • 86 Piver M S, Baker T, Piedmonte M, Sandecki A. Epidemiology and etiology of ovarian cancer.  Semin Oncol. 1991;  78 177-185
    PubMedGoogle Scholar
  • 87 Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study.  Fertil Steril. 1999;  71 853-859
    CrossrefPubMedGoogle Scholar
  • 88 Ramus S J, Fishman A, Pharoah P D, Yarkoni S, Altaras M, Ponder B A. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.  Eur J Surg Oncol. 2001;  27 278-281
    CrossrefPubMedGoogle Scholar
  • 89 Redd W H, Montgomery G H, DuHamel K. Behavioral intervention for cancer treatment side effects.  J Natl Cancer I. 1001;  93 810-823
    PubMedGoogle Scholar
  • 90 Risch H A. Estrogen replacement therapy and risk of epithelial ovarian cancer.  Gynecol Oncol. 1996;  63 254-257
    CrossrefPubMedGoogle Scholar
  • 91 Risch H A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.  J Natl Cancer I. 1998;  90 1774-1786
    PubMedGoogle Scholar
  • 92 Risch H A, Howe G R. Pelvic inflammatory disease and the risk of epithelial ovarian cancer.  Cancer Epidem Biomar. 1995;  44 441-451
    PubMedGoogle Scholar
  • 93 Risch H A, Marrett L D, Howe G R. Parity, contraception, infertility and the risk of epithelial ovarian cancer.  Am J Epidemiol. 1994;  140 585-597
    PubMedGoogle Scholar
  • 94 Rosenberg L, Palmer J R, Rao R S. et al . A case-control study of analgesic use and ovarian cancer.  Cancer Epidem Biomar. 2000;  9 933-937
    PubMedGoogle Scholar
  • 95 Rossing M A, Daling J R, Weiss N S, Moore D E, Self S G. Ovarian tumors in a cohort of infertile women.  N Engl J Med. 1994;  331 (22) 771-776
    CrossrefPubMedGoogle Scholar
  • 96 Runnebaum I B, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk.  J Cancer Res Clin. 2001;  127 73-79
    PubMedGoogle Scholar
  • 97 Sainz de la Cuesta R, Eichhorn J H, Rice L W, Fuller A F, Nikrui N, Goff B A. Histologic transformation of benign endometriosis to early epithelial ovarian cancer.  Gynecol Oncol. 1996;  60 238-244
    CrossrefPubMedGoogle Scholar
  • 98 Schildkraut J M, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.  J Natl Cancer I. 1997;  89 932-938
    PubMedGoogle Scholar
  • 99 Schildkraut J M, Calingaert B, Marchbanks P A, Moorman P G, Rodriguez G C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.  J Nat Cancer I. 2002;  94 32-38
    PubMedGoogle Scholar
  • 100 Schmale A H, Iker H. Hopelessness as a predictor of cervical cancer.  Soc Sci Med. 1971;  5 95-100
    PubMedGoogle Scholar
  • 101 Schmale A H, Iker H P. The affect of hopelessness and the development of cancer. I. Identification of uterine cervical cancer in woman with atypical cytology.  Psychosom Med. 1966;  28 714-721
    PubMedGoogle Scholar
  • 102 Schneider D, Halperin R, Bukovsky I, Hadas E. Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system.  Eur J Gynaecol Oncol. 1998;  19 547-662
    PubMedGoogle Scholar
  • 103 Schuth W. Zur psychosozialen Situation der Patientin mit ausgedehntem oder fortgeschrittenem Ovarialkarzinom.  Onkologie. 1984;  78 6-9
    PubMedGoogle Scholar
  • 104 Sevelda P, Rosen A, Barrada M, Gober S, Vavra N, Salzer H. Ist die Verlaufskontrolle falsch negativer CA-125 Serumwerte in der Tumornachsorge des Ovarialkarzinoms sinnvoll?.  Gynaekol Runds. 1990;  30 210-211
    PubMedGoogle Scholar
  • 105 Shields L B, Gercel-Taylor C, Yashar C M. et al . Induction of immune responses to ovarian tumor antigens by multiparity.  J Soc Gynecol Invest. 1997;  4 298-304
    CrossrefPubMedGoogle Scholar
  • 106 Shu X O, Brinton L A, Gao Y T, Yuan J M. Population-based case-control study of ovarian cancer in Shanghai.  Cancer Res. 1989;  49 3670-3675
    PubMedGoogle Scholar
  • 107 Shu X O, Gao Y T, Yuan J M. et al . Dietary factors and epithelial ovarian cancer.  Brit J Cancer. 1989;  59 92-96
    PubMedGoogle Scholar
  • 108 Shushan A, Paltiel O, Schenker J G. Induction of ovulation and borderline ovarian cancer - the hormonal connection?.  Eur J Obstet Gyn R B. 1999;  85 71-74
    PubMedGoogle Scholar
  • 109 Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.  Int J Gynecol Cancer. 2001;  11 119-129
    CrossrefPubMedGoogle Scholar
  • 110 Sklar L S, Anisman H. Stress and cancer.  Psychol Bull. 1981;  89 369-406
    CrossrefPubMedGoogle Scholar
  • 111 Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study.  Ann Oncol. 2000;  11 1171-1173
    CrossrefPubMedGoogle Scholar
  • 112 Taylor D D, Homesley H D, Doellgast G J. Identification of antigenic components recognized by “membran bound” antibodies from ovarian cancer patients.  Am J Reprod Immunol. 1991;  15 369-377
    PubMedGoogle Scholar
  • 113 Umesaki N, Tanaka T, Miyama M, Mizuno K, Kawamura N, Ogita S. Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist.  Gynecol Obstet Invest. 1999;  48 66-68
    CrossrefPubMedGoogle Scholar
  • 114 Van den Berghe H, Dal Cin P. Some genetic aspects of ovarian tumors.  Eur J Obstet Gyn R B. 1998;  81 283-287
    PubMedGoogle Scholar
  • 115 Van Leeuwen F E, Rookus M A. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer.  Eur J Cancer Clin On. 1989;  25 1961-1972
    PubMedGoogle Scholar
  • 116 Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation.  Lancet. 1999;  354 1586-1590
    CrossrefPubMedGoogle Scholar
  • 117 Vessey M, Metcalfe A, Wells C, Mcpherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives.  Br Med J. 1987;  294 1518-1520
    PubMedGoogle Scholar
  • 118 von Georgi R, Schubert K, Franke F E, Münstedt K. Auswirkungen soziomedizinischer Risikofaktoren auf den Verlauf des Ovarialkarzinoms.  Dtsch Med Wochenschr. 2002;  127 2001-2005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 119 Webb P M, Bain C J, Purdie D M, Harvey P WJ, Green A. Milk consumption, galactose metabolism and ovarian cancer (Australia).  Cancer Cause Control. 1998;  9 637-644
    PubMedGoogle Scholar
  • 120 Weiss N S, Harlow B L. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer?.  Am J Epidemiol. 1989;  124 856
    PubMedGoogle Scholar
  • 121 Whiteman D C, Murphy M FG, Cook L S. et al . Multiple births and risk of epithelial ovarian cancer.  J Natl Cancer I. 2000;  92 1172-1177
    PubMedGoogle Scholar
  • 122 Whittemore A S, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white woman. Collaborative ovarian cancer group.  Am J Epidemiol. 1992;  136 1184-1203
    PubMedGoogle Scholar
  • 123 Whittemore A S, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative ovarian cancer group.  Am J Epidemiol. 1992;  136 1212-1220
    PubMedGoogle Scholar
  • 124 Whittemore A S, Harris R, Itnyre J, Halpern J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative ovarian cancer group.  Am J Epidemiol. 1992;  136 1175-1183
    PubMedGoogle Scholar
  • 125 Wise P M. Neuroendocrine modulation of the “menopause”: insights into the aging brain.  Am J Physiol-Endoc M. 1999;  277 965-970
    PubMedGoogle Scholar
  • 126 Wong C, Hempling R E, Piver M S, Natarajan N, Mettlin C J. Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study.  Obstet Gynecol. 1999;  93 372-376
    CrossrefPubMedGoogle Scholar
  • 127 Wu M L, Whittemore A S, Paffenbarger R S. et al . Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use.  Am J Epidemiol. 1988;  128 1216-1227
    PubMedGoogle Scholar
  • 128 Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression.  J Natl Cancer I. 2000;  92 1472-1489
    PubMedGoogle Scholar
  • 129 Zheng W, Lu J J, Luo F. et al . Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.  Gynecol Oncol. 2000;  76 80-88
    CrossrefPubMedGoogle Scholar
  • 130 Zuckermann M. Psychobiology of Personality. New York, Port Chester, Melbourne, Sydney; Cambridge University Press 1991
    Google Scholar

Dr. Richard von Georgi

Abteilung für Medizinische Soziologie, Justus-Liebig-Universität Gießen

Friedrichstraße 24

35392 Gießen

Email: richard.v.georgi@psycho.med.uni-giessen.de

      >